Comparison of US Pharmacopeia Simulated Intestinal Fluid TS (without pancreatin)

Similar documents
DISSOLUTION TEST FOR SOLID ORAL DOSAGE FORMS. Proposal for revision for The International Pharmacopoeia. (February 2018)

Plop Plop, Fizz Fizz, Oh What A Relief It Is (Which Pain Reliever Works Fastest)

Plop Plop, Fizz Fizz, Oh What A Relief It Is (Which Pain Reliever Works Fastest)

ANALYTICAL METHOD PROCEDURES

Solubility and Dissolution Rate Determination of Different Antiretroviral Drugs in Different ph Media Using UV Visible Spectrophotometer

DETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

Research Article. Dissolution Study of Oxolamine Citrate by UV Spectrophotometric Method in Pharmaceutical Dosage Form

The Nitrofurantoin Capsules Revision Bulletin supersedes the currently official monograph.

Md.Khairul Alam et al / Journal of Pharmaceutical Science and Technology Vol. 3 (6), 2011,

SPECIALIZED LABORATORY of pharmaceuticals manufacturing

Chapter 4: Verification of compendial methods

NEVIRAPINE ORAL SUSPENSION Final text for addition to The International Pharmacopoeia (February 2009)

Practical Pharmaceutical Technology I USP Dissolution Method for PARACETAMOL 500 mg Tablets Section No. 6 Group D

Should you have any questions, please contact Mary P. Koleck, Ph.D., Scientific Liaison ( or

Scholars Research Library

Revision Bulletin 27 Jan Feb 2017 Non-Botanical Dietary Supplements Compliance

104 Full Text Available On Research Article!!! Pharmaceutical Sciences. Received: ; Accepted:

Development of Discriminating Method for Dissolution of Aceclofenac Marketed Formulations

Dissolution Method Development and Validation of Paracetamol Aceclofenac Tablets

Revision Bulletin 29 Dec Jan 2018 Non-Botanical Dietary Supplements Compliance

Development and Validation of a HPLC Method for Chlorphenamine Maleate Related Substances in Multicomponents Syrups and Tablets

CHAPTER V ANALYTICAL METHODS ESTIMATION OF DICLOFENAC. Diclofenac (gift sample from M/s Micro Labs Ltd., Pondicherry)

LABORATORY EXERCISE: USING SPECTROPHOTOMETRY FOR QUALITY CONTROL: NIACIN

Enteric coating is a widely used technique for

To assess product performance and the quality of

Monitoring Dissolution Rate of Amiodarone Tablets by a Multiple Fiber-Optic Sensor System

SIMULTANEOUS DETERMINATION OF PROCAINE AND BENZOIC ACID BY DERIVATIVE SPECTROMETRY

Scientific Principles and Advanced Concepts in Dissolution

King Saud University College of Pharmacy Department of Pharmaceutics. Biopharmaceutics PHT 414. Laboratory Assignments 2010 G 1431 H

Simultaneous UV Spectrophotometric Method for the Estimation of Cefuroxime Axetil and Probenecid from Solid Dosage Forms

CYCLOSERINE Final text for addition to The International Pharmacopoeia. (November 2008) CYCLOSERINUM CYCLOSERINE

LUMEFANTRINUM LUMEFANTRINE

Automated determination of the uniformity of dosage in quinine sulfate tablets using a fiber optics autosampler

Int. J. Pharm. Sci. Rev. Res., 30(2), January February 2015; Article No. 09, Pages: 63-68

Modernizing the USP Monograph for Acetaminophen

Fasted State Dissolution Protocol

STUDY OF THE APPLICABILTY OF CONTENT UNIFORMITY AND DISSOLUTION VARIATION TEST ON ROPINIROLE HYDROCHLORIDE TABLETS

Chemistry Determination of Mixed Acids

BRIEFING. (EXC: K. Moore.) RTS C Propylparaben C 10 H 12 O Benzoic acid, 4 hydroxy, propyl ester; Propyl p hydroxybenzoate [ ].

Development of Validated Analytical Method of Mefenamic Acid in an Emulgel (Topical Formulation)

EFAVIRENZ Final text for addition to The International Pharmacopoeia

contents of the currently official monograph. Please refer to the current edition of the USP NF for official text.

Sample Preparation of Electronic Device Components for Hexavalent Chromium Analysis by IEC Method :2017

Egualen Sodium Granules

contents of the currently official monograph. Please refer to the current edition of the USP NF for official text.

Validated First Order Derivative Spectroscopic Method for the determination of Stavudine in Bulk and Pharmaceutical Dosage Forms

Journal of Drug Delivery and Therapeutics

Sodium Chloride - Analytical Standard

Rapid Determination of Ionization Constants (pk a ) by UV Spectroscopy Using 96-well Microtiter Plates

Dissolution study and method validation of alprazolam by high performance liquid chromatography method in pharmaceutical dosage form

BRIEFING. Pharmacopeial Discussion Group Sign Off Document Attributes EP JP USP Definition Loss on drying Readily carbonizable substances

Aripiprazole tablets: Development and Validation of a Dissolution Methodology

8. FORMULATION OF LANSOPRAZOLE NANOPARTICLES

Mashhour Ghanem 1 and Saleh Abu-Lafi 2 * ABSTRACT ARTICLE INFO

Measurement of Intrinsic Drug Dissolution Rates Using Two Types of Apparatus

Spectroscopic Method For Estimation of Atorvastatin Calcium in Tablet Dosage Form

Draft Method proposal: determination of glucoheptonic acid (HGA) in fertilizers.

CHAPTER-3 MATERIALS AND METHODS

The Isosorbide Mononitrate Extended-Release Tablets Revision Bulletin supersedes the currently official monograph.

of nm throughout the experimental work.

CHAPTER - 3 ANALYTICAL PROFILE. 3.1 Estimation of Drug in Pharmaceutical Formulation Estimation of Drugs

ISO INTERNATIONAL STANDARD. Soil quality Determination of ph. Qualité du sol Détermination du ph. Second edition

BCH312 [Practical] 1

Supplementary information 1. INSTRUCTIONS FOR STUDENTS

SpeedDigester K-436, K-439 / KjelFlex K-360 Nitrogen Determination in Pharmaceuticals according to the Kjeldahl Method (semi-micro)

Ondansetron Hydrochloride Tablets

1.2 Systematic Name: D-Amino acid: oxygen reductase (deaminating)

1 st European Union Science Olympiad in Dublin, Ireland. task B

Strikingly different miscibility of n-octanol in highly-confined and quasi-confined water

Textiles - Determination of ph of Aqueous Extract

Additionally, minor editorial changes have been made to update the monograph to current USP style.

7. Stability indicating analytical method development and validation of Ramipril and Amlodipine in capsule dosage form by HPLC.

Method Development and Validation Of Prasugrel Tablets By RP- HPLC

ARTEMETHER AND LUMEFANTRINE TABLETS: Final text for addition to The International Pharmacopoeia (July 2008)

Chromazurol S Method Method to 0.50 mg/l Al TNTplus 848

VALIDATION OF A UPLC METHOD FOR A BENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDE TOPICAL SOLUTION

PRACTICAL 3 ph AND BUFFERS

Physicochemical Characterization of Binary Ionic Polymer Blends: Polyvinyl Acetate Phthalate and Eudragit E PO

Tetraphenylborate Method Method to 7.0 mg/l K Powder Pillows

OMCL Network of the Council of Europe QUALITY MANAGEMENT DOCUMENT

Ions in Solution. Solvent and Solute

Method development and validation for the estimation of metronidazole in tablet dosage form by UV spectroscopy and derivative spectroscopy

DEVELOPMENT AND VALIDATION OF A HPLC METHOD FOR IN-VIVO STUDY OF DICLOFENAC POTASSIUM

KHAN HAJERA*, MIRZA SHAHED. Y.B. Chavan College of Pharmacy, Dr. Rafiq Zakaria Campus, Rauza Bagh, Aurangabad

Appendix: 1. Sodium bicarbonate 0.84 gm (10 mm/l) 50ml of 2% sodium carbonate in 0.10N sodium hydroxide

Carbonate content. SCAN-N 32:98 Revised White, green and black liquors and burnt lime sludge

IMPROVEMENT OF DISSOLUTION PROFILE OF LORNOXICAM BY SOLID DISPERSION USING SPRAY DRYING TECHNIQUE

MEDROXYPROGESTERONE INJECTION

Work plan & Methodology: HPLC Method Development

Validated spectrophotometric determination of Fenofibrate in formulation

Self-assembly of PEGylated Gold Nanoparticles. with Satellite Structures as Seeds

Chapter 17. Additional Aspects of Equilibrium

USP 36 Official Monographs / Metformin carding the first 3 ml of filtrate. Transfer 25 ml of the Analysis

Dimethylglyoxime Method Method to 6.0 mg/l Ni TNTplus 856

Chromotropic Acid Method Method to 30.0 mg/l NO 3 N (HR) Test N Tube Vials

Journal of Chemical and Pharmaceutical Research, 2017, 9(1): Research Article

Cu-Creatinine- Metol system

Dehydrated Alcohol. » Dehydrated Alcohol contains not less than 99.2 percent, Pharmacopeial Forum Vol. 30(5) [Sept. Oct. 2004] HARMONIZATION 1847

Cadmium Reduction Method Method to 0.50 mg/l NO 3 N (LR) Powder Pillows

International Journal of Pharma and Bio Sciences

Transcription:

dx.doi.org/10.14227/dt110204p6 Comparison of US Pharmacopeia Simulated Intestinal Fluid TS (without pancreatin) and Phosphate Standard Buffer ph 6.8, TS of the International Pharmacopoeia with Respect to Their Use in In Vitro Dissolution Testing Erika Stippler 1,2, Sabine Kopp 3,4, Jennifer B. Dressman 1,5 email:dressman@em.uni-frankfurt.de Introduction Buffer solutions suitable for dissolution tests are described as such only in The United States Pharmacopeia (USP);The International Pharmacopoeia (IntPh),for example,broadly describes the composition of buffer solutions without specifying their fields of applicability. In this study Simulated Intestinal Fluid (SIFsp),which is described in The 26th United States Pharmacopeia (USP 26) as an 0.05 M buffer solution containing potassium dihydrogen phosphate (the pancreatin is omitted from the composition for most dissolution testing applications),and Phosphate Standard Buffer ph 6.8 TS, which is described in Volume 1 of The International Pharmacopoeia,Third Edition,(IntPh 3) as a mixture of 0.025 M potassium dihydrogen phosphate buffer solution and 0.025 M di-sodium hydrogen phosphate buffer solution,were investigated with respect to their interchangeability as dissolution test media. Both are ph 6.8 phosphate buffers,and they have similar osmolalities (114 mosmol/kg) and buffer capacities (18 meq/l/ph/unit). However, in the USP medium potassium (50mM) dominates over sodium (22mM) whereas in the IntPh buffer sodium (49.7mM) dominates over potassium (25mM). [Note: For the current investigations the IntPh phosphate buffer media was used as monographed in the 3rd edition,volume 1. With the publication of Volume 5 the composition of the buffer ph 6.8 medium has been changed. Volume 5 describes a 0.04 M disodium hydrogen phosphate buffer solution for Buffer ph 6.8.]. The applicability and the interchangeability of these two compositionally similar but not identical buffers as dissolution media was investigated for products containing one of three drug substances: Metronidazole, a typical BCS Class 1 drug, and indometacin and ibuprofen, two drugs belonging to BCS Class 2. In each case several commercial products currently available on the German market were investigated. Products included uncoated, film coated,and sugar coated tablets as well as hard gelatin capsules. Experimental Investigations Materials Chemical reference standard substances (CRS) Metronidazole CRS (lot 00616) was purchased from Aldrich (Germany), indometacin CRS (lot 0111A079) was purchased from Synopharm (Germany), and ibuprofen CRS (lot 10337012) was purchased from Caelo (Germany). Reagents All reagents used were of analytical grade and were purchased from VWR (Germany). Dissolution media The compositions of dissolution media used for in vitro dissolution testing are described in Table 1. The reagents were added to the deionized water under stirring to yield clear solutions. The ph value of the dissolution media was checked and adjusted as necessary to ph 6.8 ± 0.05 with 0.1 M sodium hydroxide or 0.1 M phosphoric acid solution. Pharmaceutical preparations The pharmaceutical preparations (all conventional immediate release solid oral dosage forms) investigated are described in Table 2. Analytical instruments Dissolution tests were performed with the USP 26 apparatus 2, using an Erweka model DT6R (Erweka, Germany) apparatus. For manual sampling 5 ml syringes fitted with stainless tubing were used. Samples were filtered immediately after sampling through PTFE filter sticks with 45 µm 6 Dissolution 1 J. W. Goethe University Frankfurt/Main, Department of Pharmaceutical Technology, Germany 2 PHAST GmbH, Homburg/Saar, Germany 3 World Health Organization, Geneva, Switzerland 4 The opinions expressed in this article are those of the author and Technologies MAY 2004 do not necessarily represent the decisions or stated policy of the World Health Organization. 5 Correspondending author, J. W. Goethe University Frankfurt/Main, Department of Pharmaceutical Technology, Biozentrum, Marie- Curie-Str. 9, 60439 Frankfurt, Germany

Table 1: Composition of dissolution media for in vitro dissolution testing Medium Simulated Intestinal Fluid, ph 6.8 1 (SIFsp); USP 26 Phosphate Standard Buffer ph 6.8 2 IntPh 3 Composition KH 2 PO 4 NaOH deionized water to KH 2 PO 4 Na 2 HPO 4 deionized water to 68.05 g 8.96 g 10.0 L 34.0 g 35.3 g 10.0 L 1 The composition of SIFsp is the same as in USP 25. 2 The composition of the Phosphate Standard Buffer ph 6.8 has been changed with the publication of Volume 5 of the IntPh. For measurements of osmotic pressure a semi-micro osmometer (Knauer, Germany) was used. The semi-micro osmometer was calibrated before use over the range from 0 mosmol/kg to 400 mosmol/kg with purified water and appropriate calibration solutions. Methods Measurements of the osmotic pressure (osmolarity) The measurement of the osmotic pressure of both dissolution media was performed according to the 4 th European Pharmacopoeia (Ph. Eur. 4) monograph, which specifies the freezing point method. The osmotic pressure of each dissolution medium was determined in triplicate. Table 2: Pharmaceutical preparations under investigation Drug substance Drug product Technol. description Expiry date IBU-Product A film coated tablets 11.2002 Ibuprofen IBU-Product B sugar coated tablets 08.2004 IBU-Product C capsules 09.2004 Indometacin INDO-Product A uncoated tablets 07.2003 INDO-Product B capsules 11.2004 Metronidazole METRO-Product A film coated tablets 06.2005 METRO-Product B uncoated tablets 09.2004 Buffer capacity The buffer capacity was determined according to the titration method and reported as the volume of strong acid added to one liter buffer solution to lower its ph by one unit. This was determined by adding 1 N hydrochloric acid solution drop-wise from a 25 ml buret into the 100 ml sample buffer solution, with constant stirring, until the ph decreased by one ph unit. The investigations were performed in triplicate for each dissolution medium. Table 3: Description of the methods for dissolution testing Parameter of the method Method 1 Method 2 Apparatus paddle paddle Dissolution medium Simulated Intestinal Fluid, ph 6.8 (USP 26) pore size. The dissolution system used was calibrated to meet USP apparatus suitability test requirements. A UV-Vis spectrophotometer model DU 640i (Beckmann Coulter, Germany) was used to analyze the samples for dissolved drug. The instrument was calibrated periodically according to the Pharmacopeial requirements. For the ph measurements of dissolution media an MP 230 ph meter (Mettler Toledo, Germany), calibrated daily, was used. In vitro dissolution In vitro dissolution tests were performed with the paddle apparatus in 500 ml dissolution media at 75 rpm. The dissolutions were run in accordance with the requirements of Ph. Eur. 4/ USP 26. Pre-measured volumes of dissolution media were degassed and then immediately transferred into the vessels. The tablets were placed in the vessels at the beginning of each test and the stopwatch was started simultaneously. Vessels were covered during the run with plastic covers in order to minimize evaporation. The temperature in the vessels was maintained at 37+0.5 C throughout each dissolution run. The revolution rate was checked during all tests. Samples were removed manually using 5 ml syringes fitted with stainless tubing to ensure reproducibility of the sampling location. Samples were filtered immediately after sampling through 45 µm PTFE filter sticks. The parameters used for the in vitro dissolution testing are described in Table 3. Phosphate Standard Buffer ph 6.8 (IntPh 3) Degassing yes yes Volume 500 ml 500 ml Agitation 75 rpm 75 rpm Temperature 37 C 37 C Sampling time 10, 20, 30, 45, 60 min 10, 20, 30, 45, 60 min 7

Analysis The percent of drug dissolved at each sampling time point was determined for each drug product by UV analysis. The UV measurements were performed in all cases at the wavelength of the relative maximum absorption of the drug substance, which was determined prior to each analysis. Calculation of % dissolved drug Reference standard solutions were prepared by separately weighing portions of the chemical reference standard substance. Reference standard solutions were prepared and processed using the same method as for the preparation of the sample solutions. In order to avoid potential analytical interferences, standard solutions were prepared with aliquots of the same medium used for dissolution testing. For each individual dissolution media UV-spectra between 200 nm and 400 nm of a typical blank solution, a typical sample solution, and the chemical reference standard solution were recorded. The relative maximum of the absorption spectrum was determined. By comparison of the recorded spectra, interference between the drug and the excipients dissolved in the medium was evaluated. Concentrations of drug were calculated according to the external standard method with a linear calibration plot. The linearity of the calibration function was confirmed for each individual analytical sequence at three concentrations within the working range. The in-study validation for each sequence also included a check of the repeatability by six-fold measurement of reference standard solutions. Results and Discussion Osmotic pressure and buffer capacity The results of the investigations on the osmotic pressure and buffer capacity of both dissolution media are given in Table 4. The two media are practically identical with respect to ph, buffer capacity, ionic strength and osmotic pressure. Figure 1.1. In vitro dissolution behavior of IBU-Product A film coated tablets. Arithmetic means (n=6) are shown, standard deviations were within the symbols. Figure 1.2. In vitro dissolution behavior of IBU-Product B sugar coated tablets. Arithmetic means (n=6) with standard deviations are shown. Table 4: Osmolarity, ionic strength and buffer capacity of the two buffers Medium Simulated Intestinal Fluid, ph 6.8 (SIFsp); USP 26 Phosphate Standard Buffer ph 6.8 (IntPh 3) Osmolarity [mosmol/kg] Ionic strength [mol/l] Buffer capacity [meq/l/ph unit] 113 0.0720 18.4±0.2 115 0.0753 18.6±0.1 Figure 1.3. In vitro dissolution behavior of IBU-Product C capsules. Arithmetic means (n=6) with standard deviations are shown. 8 Dissolution Technologies MAY 2004

Figure 2.1. In vitro dissolution behavior of INDO-Product A uncoated tablets. Arithmetic means (n=6) with standard deviations are shown. Figure 3.1. In vitro dissolution behavior of METRO-Product A film coated tablets. Arithmetic means (n=6) with standard deviations are shown. Figure 2.2. In vitro dissolution behavior of INDO-Product B capsules. Arithmetic means (n=6) with standard deviations are shown. Figure 3.2. In vitro dissolution behavior of METRO-Product B uncoated tablets. Arithmetic means (n=6) with standard deviations are shown Therefore, dissolution behavior is expected to be similar in the two media for majority of products. Only in a specific case where the cation (Na + vs. K + ) may have an influence, would a difference in results be anticipated. Dissolution Characterization Excipient interference: Interference of excipients did not exceed 5% for any of the products tested. Any interference was taken into consideration in calculating % dissolved, as described in the methods section. Drug products containing ibuprofen Mean in vitro dissolution behavior of various dosage forms containing ibuprofen under the two testing conditions are depicted in Figures 1.1 to 1.3. No difference in the dissolution behavior of IBU-Product A film coated tablets was observed and dissolution was complete in both media within 10 minutes. The dissolution profiles are superimposable and meet USP specifications. A small difference in the initial dissolution behavior of IBU-Product B sugar coated tablets was observed. In both media the dissolution of IBU-Product B sugar coated tablets was complete within 20 minutes. The dissolution profiles are similar and both meet USP dissolution specifications. Little or no difference in the dissolution behavior of IBU- Product C capsules was observed. Even though the dissolution profiles for this product are quite different from the other two products, they meet USP specifications. The difference is attributable to the dissolution time of the capsule shell. Drug products containing indometacin The in vitro dissolution behavior of two indometacin drug products (one uncoated tablet and one capsule 9

formulation) under the two testing conditions are depicted in Figures 2.1 and 2.2. Little difference in the dissolution behavior of INDO- Product A uncoated tablets was observed. The amount of the drug dissolved in Phosphate Standard Buffer ph 6.8 was slightly lower in comparison to that in SIFsp, but the shape of the dissolution profiles are similar and both profiles meet USP specifications. No difference in the dissolution behavior of INDO- Product B capsules was observed. The dissolution profiles are superimposable and meet USP specifications. Drug products containing metronidazole The in vitro dissolution behavior of two metronidazole drug products (one film coated and one uncoated tablet formulation) under the two testing conditions are depicted in Figures 3.1 and 3.2. Little difference in the dissolution behavior of METRO- Product A film coated tablets in the two media was observed. The shapes of the dissolution profiles are similar and both profiles meet USP specifications. Slight differences in the dissolution behavior of METRO- Product B uncoated tablets were observed. The amount of the drug dissolved at 10 minutes in Phosphate Standard Buffer ph 6.8 (IntPh 3) was slightly lower and after 20 minutes slightly higher in comparison to that in SIFsp. However, both profiles easily meet USP specifications. Conclusions Dissolution results were found to be similar in the three cases investigated. This is not surprising, since ph, buffer capacity, ionic strength and osmolarity of the two buffers are almost identical. In fact, the distinguishing factor between the two media rests solely in the ratio of sodium to potassium. The results of these studies suggest that changing the proportions of these two cations in the medium makes little or no difference to the dissolution results. For the purposes of dissolution testing of conventionally formulated immediate release solid oral dosage forms, the Phosphate Standard Buffer ph 6.8 of the IntPh 3 can be generally considered interchangeable with SIFsp of the USP 26. Only in specific cases where solubility is known to be affected by the cation does one need to be wary about substitution of the two cations for each other. In an upcoming report, we will address this issue using the dissolution of phenytoin sodium capsules in sodium lauryl sulfate containing media as a case example. References 1. United States Pharmacopeia and National Formulary, United States Pharmacopeial Convention Inc., Rockville, MD, USA, 25th Edition (2002) and 26th Edition (2003) 2. The International Pharmacopoeia, WHO, Geneva, Switzerland, 3rd Edition, Volume 1 (1979) and Volume 5 (2003) 3. European Pharmacopoeia, European Directorate for the Quality of Medicines of the Council of Europe (EDQM), Strassbourg, France, 4th Edition (2001) 10